CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

CA Cancer J Clin 2005; 55:242-258
doi: 10.3322/canjclin.55.4.242
© 2005 American Cancer Society
This Article
Right arrow Full Text Freely available
Right arrow Full Text (PDF) Freely available
Right arrow Freely available CME: Take the course for this article:
 TNM Head and Neck Staging
Right arrow Submit a letter to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Patel, S. G.
Right arrow Articles by Shah, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patel, S. G.
Right arrow Articles by Shah, J. P.

TNM Staging of Cancers of the Head and Neck: Striving for Uniformity Among Diversity

Snehal G. Patel, MD, FRCS (Glasg) and Jatin P. Shah, MD, FACS


Dr. Patel is Attending Surgeon, Head and Neck Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY.
Dr. Shah is Chief, Head and Neck Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY.

The sixth edition of the tumor-node-metastasis staging system for head and neck cancers incorporates some significant shifts in philosophy. As treatment paradigms shift and data from ongoing clinical and basic research become available, further revisions may be expected in the future. The purpose of this review is to highlight the complexities involved in developing a user-friendly staging system and to report the major changes in the new version. The authors also discuss some areas of current interest that may have the potential to lead to future modifications.




This article has been cited by other articles:


Home page
 Anticancer ResHome page
J. RIES, N. MOLLAOGLU, E. VAIRAKTARIS, F. W. NEUKAM, and E. NKENKE
Diagnostic and Therapeutic Relevance of NY-ESO-1 Expression in Oral Squamous Cell Carcinoma
Anticancer Res, December 1, 2009; 29(12): 5125 - 5130.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
C. CORDES, A.-K. MUNZEL, P. RUDOLPH, M. HOFFMANN, I. LEUSCHNER, and S. GOTTSCHLICH
Immunohistochemical Staining of Ki-67 Using the Monoclonal Antibody Ki-S11 Is a Prognostic Indicator for Laryngeal Squamous Cell Carcinoma
Anticancer Res, April 1, 2009; 29(4): 1459 - 1465.
[Abstract] [Full Text] [PDF]

Home page
 cfpHome page
P. Mehanna and G. Smith
Maxillary carcinoma: A wolf in sheep's clothing
Can Fam Physician, March 1, 2009; 55(3): 262 - 264.
[Full Text] [PDF]

Home page
 JNMHome page
S. C. Ong, H. Schoder, N. Y. Lee, S. G. Patel, D. Carlson, M. Fury, D. G. Pfister, J. P. Shah, S. M. Larson, and D. H. Kraus
Clinical Utility of 18F-FDG PET/CT in Assessing the Neck After Concurrent Chemoradiotherapy for Locoregional Advanced Head and Neck Cancer
J. Nucl. Med., April 1, 2008; 49(4): 532 - 540.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by American Cancer Society.